Prognostic impact of discrepant Ki67 and mitotic index on hormone receptor-positive, HER2-negative breast carcinoma.

Br J Cancer · 2015 · PMC4651130 · PMID 26379080

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

almost significantlyP =0.06so close (0.05 < p ≤ 0.1)

In our study, the analysis of BCSS ( Supplementary Figure ) or DFS of HR+ HER− patients did not seem to be affected by the PR status (cutoff 20% ( Prat et al , 2013 )); however, in the discrepant group patients with PR ⩾20% had almost significantly better BCSS (HR=0.50, 95% CI (0.15–1.06), log-rank P =0.06).

also in 555 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.